Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2)

Journal of Controlled Release

Volumn 57, Issue 2, 1999, Pages 161-169

  MacIas, Rocio I R ^a   El Mir, Mohamad Y ^a   Monte, Maria J ^a   Serrano, Maria A ^a   Garcia, Maria J ^a   Marin, Jose J G ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Bile acid; Cancer; Chemotherapy; Kidney; Liver; Metal; Pharmacokinetics; Platinum; Tumor

Indexed keywords

BAMET R2; CISPLATIN; CISPLATIN DERIVATIVE; GLYCOCHOLIC ACID; PLATINUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FECES LEVEL; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ILEUM; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORGAN PERFUSION; PRIORITY JOURNAL; RAT; REGIONAL PERFUSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG CARRIERS; GLYCOCHOLIC ACID; ILEUM; INJECTIONS, INTRAVENOUS; INTUBATION, GASTROINTESTINAL; ORGANOPLATINUM COMPOUNDS; PERFUSION; PLATINUM; RATS; SPECTROPHOTOMETRY, ATOMIC;

EID: 0032943865     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(98)00114-X     Document Type: Article

References (32)

1. Ho N.F.H. Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption. Ann. New York Acad. Sci. 907:1987;315-329.
2. Betebenner D.A., Carney P.L., Zimmer A.M., Kazikiewicz J.M. Hepatobiliary delivery of polyaminopolycarboxylate chelates: Synthesis and characterization of a cholic acid conjugate of EDTA and biodistribution and imaging studies with its indium-111 chelate. Bioconjugate Chem. 2:1991;117-123.
3. Stephan Z.F., Yurachek E.C., Sharif R., Wasvary J.M., Steele R.E., Howes C. Reduction of cardiovascular and thyroxine-suppressing activities of L-T3 by liver targeting with cholic acid. Biochem. Pharmacol. 43:1992;1969-1974.
4. Kramer W., Wess G., Schubert G., Bickel M., Girbig F., Gutjahr U., Kowalewski S., Baringhaus K.H., Enhsen A., Glombik H., Mullner S., Neckermann G., Schulz S., Petzinger E. Liver-specific drug targeting by coupling to bile acids. J. Biol. Chem. 267(26):1992;18598-18604.
5. Criado J.J., Macias R.I.R., Medarde M., Monte M.J., Serrano M.A., Marin J.J.G. Synthesis and characterization of the new cytostatic complex cis-diammineplatinum(II)-chlorocholylglycinate. Bioconjugate Chem. 8:1997;453-458.
6. A.F. Hofmann, Biliary secretion and excretion - the hepatobiliary component of the enterohepatic circulation of bile acids, in: L.R. Johnson (Ed.), Physiology of the Gastrointestinal Tract, Raven Press, New York, 1994, pp. 1555-1576.
7. Kramer W., Wess G. Bile acid transport systems as pharmaceutical targets. Eur. J. Clin. Invest. 26:1996;715-732.
8. R.I.R. Macias, M.J. Monte, M.Y. El-Mir, G.R. Villanueva, J.J.G. Marin, Transport and biotransformation of the new cytostatic complex cis-diamineplatinum(II)-chlorocholylglycinate (Bamet-R2) by the rat liver, J. Lipid Res. 39 (1998) in press.
9. Meijer D.K.F. Drug targeting to the liver with bile acids-The Trojan Horse resurrected. Hepatology. 17:1993;945-948.
10. Kroker R., Anwer M.S., Hegner D. The lack of active bile acid transport in AS-30D ascites hepatoma cells. Naunyn Schmiedeberg's Arch. Pharmacology. 303:1978;299-301.
11. Buscher H.P., Gerok W., Kollinger M., Kurz G., Muller M., Nolte A., Schneider S. Transport systems for amphipathic compounds in normal and neoplastic hepatocytes. Adv. Enzyme Regul. 27:1988;173-192.
12. Von Dippe P., Levy D. Expression of the bile acid transport proteins during liver development and in hepatoma cells. J. Biol. Chem. 265:1990;5942-5945.
13. Kullak-Ublick G.A., Beuers U., Paumgartner G. Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology. 23:1996;1053-1060.
14. Marchegiano P., Carubbi F., Tiribelli C., Amarri S., Stebel M., Lunazzi G.C., Levy D., Bellentani S. Transport of sulfobromophthalein and taurocholate in the HepG2 cell line in relation to the expression of membrane carrier proteins. Biochem. Biophys. Res. Commun. 183:1992;1203-1208.
15. M. Miyazaki, M. Namba, Hepatocellular Carcinomas, in: R.J. Hay, J.G. Park, A. Gazdar (Eds.), Atlas of Human Tumor Cell Lines, Academic Press, Inc., San Diego, 1994, pp. 185-221.
16. Campbell A.B., Kalman S.M., Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat. Rep. 67:1983;169-172.
17. Kelsen D.P., Alcock N., Young C.W. Cisplatin nephrotoxicity. Correlation with plasma concentrations. Am. J. Clin. Oncol. 8:1985;77-80.
18. Desoize B., Marechal F., Millart H., Cattan A. Correlation of clinical pharmaco-kinetic parameters of cisplatin with efficacy and toxicity. Biomed. Pharmacother. 45:1991;203-207.
19. Desoize B., Robert J. Individual dose adaptation of anticancer drugs. Eur. J. Cancer. 30:1994;844-851.
20. Ma J., Verweij J., Kolker H.J., Vaningen H.E., Stoter G., Schellens J.H.M. Pharmacokinetic-dynamic relationship of cisplatin in vitro: Simulation of an iv bolus and 3 h and 20 h infusion. Br. J. Cancer. 69:1994;858-862.
21. Desoize B., Berthiot G., Manot L., Coninx P., Dumont P. Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. Eur. J. Cancer. 32:1996;1734-1738.
22. Yamaoka K., Nakagawa T., Uno T. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6:1978;547-557.
23. Hylemon P.B. Metabolism of bile acids in intestinal microflora. New Compr. Biochem. 12:1985;331-343.
24. Binks S.P., Dobrota M. Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine. Biochem. Pharmacol. 40:1990;1329-1336.
25. Goel R., Andrews P.A., Pfeifle C.E., Abramson I.S., Kirmani S., Howell S.B. Comparison of the pharmacokinetics of ultrafiltrable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy. Eur. J. Cancer. 26:1990;21-27.
26. Almé B., Bremmelgaard A., Sjovall J., Thomassen P. Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas-liquid chromatography-mass spectrometry. J. Lipid Res. 18:1977;339-362.
27. Marin J.J.G., Herrera M.C., Palomero M.F., Macias R.I.R., Monte M.J., Villanueva G.R., El-Mir M.Y., Serrano M.A., Criado J.J. 'In vivo' distribution, toxicity and cytostatic capacity of platinated bile acid analogs [Abstract]. Hepatology. 24:1996;372A.
28. DeConti R.C., Toftness B.R., Lange R.C., Creasey W.A. Clinical and pharmacological studies with cis-diammineplatinum(II). Cancer Res. 33:1973;1310-1315.
29. Gromley P.E., Bull J.M., LeRoy A.F., Cysyk R. Kinetics of cis-dichlorodiammineplatinum. Clin. Pharmacol. Ther. 25:1979;351-357.
30. Gonzalez-Vitale J.C., Hayes D.M., Cvitkovic E., Sternberg S.S. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 39:1977;1362-1371.
31. Daugaard G., Abildgaard U., Holstein-Rathlou N.H., Bruunshuus I., Bucher D., Leyssac P.P. Renal tubular function in patients treated with high-dose cisplatin. Clin. Pharmacol. 44:1988;164-172.
32. Daugaard G., Rossing N., Rorth M. Effect of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother. Pharmacol. 21:1988;163-167.